Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Posted on by ScienceFather

Prof. Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Prof. Ammu Kutty Radhakrishnan, Monash University Malaysia, Malaysia

 

Prof. Ammu Kutty Radhakrishnan is a distinguished immunologist with a PhD from the University of Cambridge (1994), an MSc in Biochemistry (1990), and a BSc (First Class Honours) from the University of Malaya (1987). Currently, a Professor of Immunology at Monash University Malaysia, she has over 25 years of academic leadership and research experience. Prof. Ammu specializes in immunotherapy and food as medicine research, serving as Head of this research strength. Her career spans significant roles at International Medical University and Oxford. She is a research consultant, active in COVID-19 vaccine efforts, and supervises PhD and MSc students. 🌿🧬📚

 

Publication Profile

Google Scholar

Academic Excellence

Prof. Ammu Kutty Radhakrishnan has an exceptional academic background, with a PhD in Immunology from the University of Cambridge (1994) and degrees in Biochemistry from the University of Malaya. Her education forms a solid foundation for her expertise in immunology and biomedical sciences, contributing to her distinguished career.

Professional Experience

Prof. Radhakrishnan has held key roles, such as Professor at Monash University Malaysia and the International Medical University (IMU). Her leadership in academic programs, such as head of the Food as Medicine Research Strength and chief examiner roles, showcases her commitment to advancing education and research.

Research Contributions

Prof. Radhakrishnan has supervised numerous PhD and Master’s students, guiding 39 doctoral and 20 master’s research projects to completion. Her extensive research supervision experience highlights her dedication to fostering scientific inquiry and innovation. Additionally, her collaborative efforts with industry partners demonstrate her ability to apply research to real-world problems.

Conclusion

Prof. Ammu Kutty Radhakrishnan’s outstanding academic credentials, extensive research supervision, leadership roles, and global health contributions, she is an ideal candidate for the Best Researcher Award. Her work in immunology, biomedicine, and collaboration with industry partners demonstrates her excellence in both academic and applied research, making her a worthy contender for this prestigious recognition.

 

Publication Top Notes  

  • Protective effect of aqueous extract from Spirulina platensis against cell death induced by free radicals (2010) – 292 citations 🧪
  • Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59 (1994) – 259 citations 🧬
  • Rind of the rambutan, Nephelium lappaceum, a potential source of natural antioxidants (2008) – 193 citations 🍇
  • Current concepts of neurodegenerative mechanisms in Alzheimer’s disease (2018) – 176 citations 🧠
  • Bioactive Compounds: Natural Defense Against Cancer? (2019) – 169 citations 🌿
  • Protective mechanisms of flavonoids in Parkinson’s disease (2015) – 162 citations 🧑‍⚕️
  • Tocotrienol research: past into present (2012) – 157 citations 🌰
  • Standardised Mangifera indica extract is an ideal antioxidant (2009) – 149 citations 🥭
  • Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease (2020) – 128 citations 🚀
  • Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice (2004) – 126 citations 🧫
  • Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity (2013) – 124 citations 🧪

 

Ken Kato | Oncology Award | Excellence in Research

Posted on by ScienceFather

Dr. Ken Kato | Oncology Award | Excellence in Research

Dr. Ken Kato, National Cancer Center Hospital, Japan

Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology 🏥. Holding both an M.D. and a Ph.D. from prestigious institutions 🎓, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer 🧬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment 📚. Dr. Kato is also an active member of several professional societies worldwide 🌏.

Publication profile

Scopus

Education

Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 🎓.

Research Focus

Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies 🧬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance 📊. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes 🚑. Dr. Kato’s research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy 🌟.

Publication Top Notes

  • A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 📅, Cited by: 0 🔍
  • ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453–463 📅, Cited by: 21 📊
  • Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863–870 📅, Cited by: 3 📈
  • Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 📅, Cited by: 41 🔬
  • Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002–1007 📅, Cited by: 24 🧬
  • Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366–374 📅, Cited by: 7 🔍
  • A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183–188 📅, Cited by: 30 🩺
  • Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522–528 📅, Cited by: 26 📊
  • Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588–2595 📅, Cited by: 33 🧪
  • Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42–49 📅, Cited by: 31 🩹